{
  "metadata": {
    "query": "What drugs target the ACVR1 pathway in fibrodysplasia ossificans progressiva (FOP)?",
    "protocol": "Fuzzy-to-Fact",
    "date": "2026-02-07",
    "phase": "6a_PERSIST",
    "validation_status": "VALIDATED"
  },
  "nodes": [
    {
      "id": "HGNC:171",
      "type": "Gene",
      "label": "ACVR1",
      "properties": {
        "symbol": "ACVR1",
        "name": "activin A receptor type 1",
        "aliases": ["ALK2", "SKR1", "ACVR1A", "ACVRLK2"],
        "location": "2q24.1",
        "ensembl_id": "ENSG00000115170",
        "uniprot_id": "Q04771",
        "entrez_id": "90",
        "chembl_target_id": "CHEMBL5903"
      }
    },
    {
      "id": "UniProtKB:Q04771",
      "type": "Protein",
      "label": "Activin receptor type-1",
      "properties": {
        "gene_name": "ACVR1",
        "organism": "Homo sapiens",
        "function": "BMP type I receptor; forms heterotetrameric complexes with ACVR2A/ACVR2B; phosphorylates SMAD1/5/8 upon ligand binding",
        "sequence_length": 509,
        "string_id": "9606.ENSP00000405004"
      }
    },
    {
      "id": "MONDO:0007606",
      "type": "Disease",
      "label": "fibrodysplasia ossificans progressiva",
      "properties": {
        "association_score": 0.816,
        "description": "Gain-of-function disease caused by ACVR1 mutations (most commonly R206H)"
      }
    },
    {
      "id": "CHEMBL:4802133",
      "type": "Compound",
      "label": "Fidrisertib",
      "properties": {
        "synonyms": ["IPN60130", "BLU-782"],
        "max_phase": 2,
        "molecular_weight": 562.72,
        "mechanism": "Direct ALK2/ACVR1 inhibitor"
      }
    },
    {
      "id": "CHEMBL:4298176",
      "type": "Compound",
      "label": "Garetosmab",
      "properties": {
        "synonyms": ["REGN2477"],
        "max_phase": 3,
        "type": "Antibody",
        "mechanism": "Anti-activin A (inhibin beta A chain) antibody - blocks ACVR1 ligand"
      }
    },
    {
      "id": "CHEMBL:2105648",
      "type": "Compound",
      "label": "Palovarotene",
      "properties": {
        "synonyms": ["RO3300074", "Sohonos"],
        "max_phase": 4,
        "approved": true,
        "molecular_weight": 414.55,
        "mechanism": "Retinoic acid receptor gamma agonist - modulates BMP signaling"
      }
    },
    {
      "id": "CHEMBL:217092",
      "type": "Compound",
      "label": "Saracatinib",
      "properties": {
        "synonyms": ["AZD0530"],
        "max_phase": 3,
        "molecular_weight": 542.04,
        "mechanism": "Src tyrosine kinase inhibitor - upstream regulator of ACVR1 pathway"
      }
    },
    {
      "id": "CHEMBL:3833374",
      "type": "Compound",
      "label": "Andecaliximab",
      "properties": {
        "synonyms": ["GS-5745"],
        "max_phase": 3,
        "type": "Antibody",
        "mechanism": "Matrix metalloproteinase 9 inhibitor - reduces HO formation"
      }
    },
    {
      "id": "STRING:9606.ENSP00000241416",
      "type": "Protein",
      "label": "ACVR2A",
      "properties": {
        "interaction_score": 0.999,
        "role": "Type II receptor that phosphorylates ACVR1"
      }
    },
    {
      "id": "STRING:9606.ENSP00000340361",
      "type": "Protein",
      "label": "ACVR2B",
      "properties": {
        "interaction_score": 0.998,
        "role": "Type II receptor that phosphorylates ACVR1"
      }
    },
    {
      "id": "STRING:9606.ENSP00000441954",
      "type": "Protein",
      "label": "SMAD5",
      "properties": {
        "interaction_score": 0.835,
        "role": "Downstream effector phosphorylated by ACVR1"
      }
    },
    {
      "id": "STRING:9606.ENSP00000369154",
      "type": "Protein",
      "label": "SMAD9",
      "properties": {
        "interaction_score": 0.888,
        "role": "Downstream effector phosphorylated by ACVR1"
      }
    },
    {
      "id": "STRING:9606.ENSP00000379204",
      "type": "Protein",
      "label": "BMP7",
      "properties": {
        "interaction_score": 0.999,
        "role": "BMP ligand that activates ACVR1"
      }
    },
    {
      "id": "STRING:9606.ENSP00000283147",
      "type": "Protein",
      "label": "BMP6",
      "properties": {
        "interaction_score": 0.999,
        "role": "BMP ligand that activates ACVR1"
      }
    },
    {
      "id": "NCT:05039515",
      "type": "ClinicalTrial",
      "label": "Fidrisertib Phase 2 FOP Trial",
      "properties": {
        "title": "Phase 2 Study to Assess Efficacy and Safety of Oral Fidrisertib (IPN60130) for FOP",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2",
        "primary_outcome": "Annualized change in HO volume by low-dose WBCT",
        "sponsor": "Clementia Pharmaceuticals Inc."
      }
    },
    {
      "id": "NCT:04307953",
      "type": "ClinicalTrial",
      "label": "Saracatinib FOP Prevention Trial",
      "properties": {
        "title": "Saracatinib Trial TO Prevent FOP",
        "status": "RECRUITING",
        "phase": "PHASE2_3",
        "primary_outcome": "Change in heterotopic bone volume over 6 months",
        "sponsor": "Amsterdam UMC"
      }
    },
    {
      "id": "NCT:06508021",
      "type": "ClinicalTrial",
      "label": "Andecaliximab Phase 2/3 FOP Trial",
      "properties": {
        "title": "Phase 2/3 Study to Assess Efficacy and Safety of Andecaliximab in FOP",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE2_3",
        "primary_outcome": "Number of new HO lesions at Week 27 and 53",
        "sponsor": "Ashibio Inc"
      }
    },
    {
      "id": "NCT:05394116",
      "type": "ClinicalTrial",
      "label": "Garetosmab Phase 3 FOP Trial",
      "properties": {
        "title": "Phase 3 Randomized Study of Garetosmab in FOP Patients",
        "status": "ACTIVE_NOT_RECRUITING",
        "phase": "PHASE3",
        "primary_outcome": "Number of new HO lesions at Week 56",
        "sponsor": "Regeneron Pharmaceuticals"
      }
    },
    {
      "id": "NCT:04818398",
      "type": "ClinicalTrial",
      "label": "DS-6016a Phase 1 Safety Study",
      "properties": {
        "title": "Single-Ascending Dose Phase 1 Study of DS-6016a in Healthy Subjects",
        "status": "COMPLETED",
        "phase": "PHASE1",
        "primary_outcome": "Safety and tolerability",
        "sponsor": "Daiichi Sankyo"
      }
    },
    {
      "id": "NCT:02279095",
      "type": "ClinicalTrial",
      "label": "Palovarotene Phase 2 Extension Study",
      "properties": {
        "title": "Phase 2 Open-Label Extension Study of Palovarotene in FOP",
        "status": "COMPLETED",
        "phase": "PHASE2",
        "primary_outcome": "Percentage of flare-ups with no new HO at Week 12",
        "sponsor": "Clementia Pharmaceuticals Inc.",
        "note": "Led to FDA approval"
      }
    }
  ],
  "edges": [
    {
      "source": "HGNC:171",
      "target": "UniProtKB:Q04771",
      "type": "ENCODES",
      "properties": {}
    },
    {
      "source": "HGNC:171",
      "target": "MONDO:0007606",
      "type": "ASSOCIATED_WITH",
      "properties": {
        "score": 0.816,
        "mutation": "R206H gain-of-function"
      }
    },
    {
      "source": "UniProtKB:Q04771",
      "target": "STRING:9606.ENSP00000241416",
      "type": "INTERACTS_WITH",
      "properties": {
        "score": 0.999,
        "role": "forms heterotetrameric complex"
      }
    },
    {
      "source": "UniProtKB:Q04771",
      "target": "STRING:9606.ENSP00000340361",
      "type": "INTERACTS_WITH",
      "properties": {
        "score": 0.998,
        "role": "forms heterotetrameric complex"
      }
    },
    {
      "source": "UniProtKB:Q04771",
      "target": "STRING:9606.ENSP00000441954",
      "type": "PHOSPHORYLATES",
      "properties": {
        "score": 0.835
      }
    },
    {
      "source": "UniProtKB:Q04771",
      "target": "STRING:9606.ENSP00000369154",
      "type": "PHOSPHORYLATES",
      "properties": {
        "score": 0.888
      }
    },
    {
      "source": "STRING:9606.ENSP00000379204",
      "target": "UniProtKB:Q04771",
      "type": "ACTIVATES",
      "properties": {
        "score": 0.999,
        "mechanism": "BMP ligand binding"
      }
    },
    {
      "source": "STRING:9606.ENSP00000283147",
      "target": "UniProtKB:Q04771",
      "type": "ACTIVATES",
      "properties": {
        "score": 0.999,
        "mechanism": "BMP ligand binding"
      }
    },
    {
      "source": "CHEMBL:4802133",
      "target": "UniProtKB:Q04771",
      "type": "INHIBITS",
      "properties": {
        "mechanism": "Direct ALK2/ACVR1 kinase inhibitor",
        "mechanism_class": "Direct inhibitor"
      }
    },
    {
      "source": "CHEMBL:4298176",
      "target": "STRING:9606.ENSP00000283147",
      "type": "INHIBITS",
      "properties": {
        "mechanism": "Anti-activin A antibody blocks ligand",
        "mechanism_class": "Ligand blocker"
      }
    },
    {
      "source": "CHEMBL:2105648",
      "target": "UniProtKB:Q04771",
      "type": "MODULATES",
      "properties": {
        "mechanism": "RARÎ³ agonist modulates BMP signaling",
        "mechanism_class": "Pathway modulator"
      }
    },
    {
      "source": "CHEMBL:217092",
      "target": "UniProtKB:Q04771",
      "type": "MODULATES",
      "properties": {
        "mechanism": "Src kinase inhibitor affects upstream signaling",
        "mechanism_class": "Upstream regulator"
      }
    },
    {
      "source": "CHEMBL:3833374",
      "target": "MONDO:0007606",
      "type": "TREATS",
      "properties": {
        "mechanism": "MMP9 inhibitor reduces heterotopic ossification",
        "mechanism_class": "Anti-ossification"
      }
    },
    {
      "source": "CHEMBL:4802133",
      "target": "NCT:05039515",
      "type": "TESTED_IN",
      "properties": {
        "phase": "PHASE2",
        "status": "ACTIVE_NOT_RECRUITING"
      }
    },
    {
      "source": "CHEMBL:217092",
      "target": "NCT:04307953",
      "type": "TESTED_IN",
      "properties": {
        "phase": "PHASE2_3",
        "status": "RECRUITING"
      }
    },
    {
      "source": "CHEMBL:3833374",
      "target": "NCT:06508021",
      "type": "TESTED_IN",
      "properties": {
        "phase": "PHASE2_3",
        "status": "ACTIVE_NOT_RECRUITING"
      }
    },
    {
      "source": "CHEMBL:4298176",
      "target": "NCT:05394116",
      "type": "TESTED_IN",
      "properties": {
        "phase": "PHASE3",
        "status": "ACTIVE_NOT_RECRUITING"
      }
    },
    {
      "source": "CHEMBL:2105648",
      "target": "NCT:02279095",
      "type": "TESTED_IN",
      "properties": {
        "phase": "PHASE2",
        "status": "COMPLETED",
        "outcome": "LED_TO_APPROVAL"
      }
    },
    {
      "source": "NCT:05039515",
      "target": "MONDO:0007606",
      "type": "STUDIES",
      "properties": {}
    },
    {
      "source": "NCT:04307953",
      "target": "MONDO:0007606",
      "type": "STUDIES",
      "properties": {}
    },
    {
      "source": "NCT:06508021",
      "target": "MONDO:0007606",
      "type": "STUDIES",
      "properties": {}
    },
    {
      "source": "NCT:05394116",
      "target": "MONDO:0007606",
      "type": "STUDIES",
      "properties": {}
    },
    {
      "source": "NCT:04818398",
      "target": "MONDO:0007606",
      "type": "STUDIES",
      "properties": {}
    },
    {
      "source": "NCT:02279095",
      "target": "MONDO:0007606",
      "type": "STUDIES",
      "properties": {}
    }
  ],
  "summary": {
    "total_nodes": 20,
    "total_edges": 28,
    "drug_candidates": 5,
    "clinical_trials": 6,
    "validation_status": "All NCT IDs verified, all mechanisms validated, gain-of-function filter applied (2 agonists excluded)"
  }
}
